Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Ranbaxy, Inc.
Current Parent Company: Sun Pharmaceuticals
Penalty: $485,000,000
Year: 2022
Date: September 19, 2022
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: The Indian pharmaceutical company Ranbaxy agreed to pay $485 million to resolve multi-district litigation alleging it manipulated the Food and Drug Administration's approval process to stop competitors from developing generic versions of three medications.
Level of Government: federal
Action Type: private litigation
Court: District of Massachusetts
Civil or Criminal Case: civil
Case ID: 1:19md2878
Case Name: In Re: Ranbaxy Generic Drug Application Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: India
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.